Clinical Trials Browser

NIH × cemiplimab × Dermatologic × Clear all

NCT06568172 2026-03-19

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma